Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, Texas A&M University, College Station, TX, USA.
J Feline Med Surg. 2020 Apr;22(4):313-321. doi: 10.1177/1098612X19844345. Epub 2019 Apr 15.
The aim of this retrospective descriptive study was to determine the effectiveness of using iridium implants in addition to surgery in cats with feline injection-site sarcomas (FISSs) in terms of time to progression and disease-specific survival and to identify prognostic factors for patient outcome.
Medical records of cats presented at our institution with FISS were reviewed. Inclusion criteria included histologic diagnosis of a tumor type associated with post-injection neoplastic development, tumor located at a site associated with vaccination, no other therapies prior to the administration of brachytherapy with the exception of surgery and adequate follow-up data.
Twenty-two cats with FISS were treated with surgery and brachytherapy delivered by postoperative iridium-192 interstitial implants. Radiation doses ranged from 4000 to 6000 cGy (median dose 5079.55 cGy), with most doses delivered over 7 days. The median number of surgeries prior to brachytherapy was one (range 1-4). The complications associated with postoperative brachytherapy were typically mild, although four cats developed more severe complications. The median time to progression for all cats was 619 days and disease-specific survival time for all cats was 1242 days. The 1 and 2 year tumor-free rates in these cats were 63.6% and 40.9%, respectively. The local failure rate was 54.5% and the distant failure rate was 13.6% due to lung metastasis. There was a significant difference in time to progression of cats that had a single surgery performed prior to brachytherapy and those that had multiple surgeries (undefined vs 310 days; = 0.01). There were no other statistically significant identified prognostic factors.
These data suggest that the addition of brachytherapy postoperatively in cats with FISS was well tolerated and is comparable to other forms of adjuvant therapy.
本回顾性描述性研究的目的是确定在患有猫注射部位肉瘤（FISS）的猫中，除手术外，使用铱植入物在疾病进展时间和疾病特异性生存方面的有效性，并确定患者预后的预测因素。
回顾性分析我院就诊的 FISS 猫的病历。纳入标准包括组织学诊断为与注射后肿瘤发展相关的肿瘤类型，肿瘤位于与疫苗接种相关的部位，除手术后近距离放射治疗外，无其他治疗方法，并且有足够的随访数据。
22 只患有 FISS 的猫接受了手术和近距离放射治疗，术后采用铱-192 间质植入物进行治疗。放射剂量范围为 4000 至 6000 戈瑞（中位剂量为 5079.55 戈瑞），大多数剂量在 7 天内完成。在接受近距离放射治疗之前，中位数手术次数为 1 次（范围 1-4 次）。与术后近距离放射治疗相关的并发症通常较轻，但有 4 只猫出现更严重的并发症。所有猫的疾病进展中位时间为 619 天，所有猫的疾病特异性生存时间为 1242 天。这些猫的 1 年和 2 年无肿瘤生存率分别为 63.6%和 40.9%。局部失败率为 54.5%，由于肺转移，远处失败率为 13.6%。在接受近距离放射治疗前接受单一手术的猫与接受多次手术的猫之间疾病进展时间存在显著差异（未定义 vs 310 天；P = 0.01）。没有其他具有统计学意义的预后因素。
这些数据表明，在患有 FISS 的猫中，手术后添加近距离放射治疗是可以耐受的，并且与其他辅助治疗方法相当。
